ASMB ▲ +1.6% - Assembly Biosciences, Inc.
$ASMB - Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
29-OCT-2026 04:00 PM ET
Share this post
More filings for $ASMB
ASMB ▲ +1.1% - Assembly Biosciences, Inc.Oct 5, 2026ASMB ▼ -7.2% - Assembly Biosciences, Inc.Sep 10, 2026ASMB ▼ -3.6% - Assembly Biosciences, Inc.Sep 8, 2026ASMB - Assembly Biosciences, Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026ASMB SEC Filing Update (04-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 4, 2026
View full $ASMB filing history →💬 Comments
Loading comments…
Leave a comment